Cognition Therapeutics (NASDAQ:CGTX) Stock Rating Upgraded by B. Riley

Cognition Therapeutics (NASDAQ:CGTX) was upgraded by stock analysts at B. Riley from a “neutral” rating to a “buy” rating in a report issued on Thursday, MarketBeat Ratings reports. The firm currently has a $1.50 price target on the stock, up from their prior price target of $1.00. B. Riley’s price objective indicates a potential upside of 138.06% from the stock’s previous close.

A number of other equities research analysts have also issued reports on the stock. HC Wainwright upped their price objective on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a report on Thursday. Chardan Capital reissued a “buy” rating and issued a $11.00 price target on shares of Cognition Therapeutics in a research note on Thursday. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.30.

Cognition Therapeutics Stock Down 0.6 %

Shares of NASDAQ:CGTX opened at $0.63 on Thursday. Cognition Therapeutics has a 52-week low of $0.34 and a 52-week high of $2.95. The stock has a market cap of $26.18 million, a P/E ratio of -0.65 and a beta of 1.26. The business has a fifty day moving average of $0.48 and a two-hundred day moving average of $0.93.

Institutional Trading of Cognition Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in Cognition Therapeutics in the third quarter valued at about $27,000. Sigma Planning Corp raised its stake in shares of Cognition Therapeutics by 14.6% in the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after acquiring an additional 25,050 shares during the period. Mercer Global Advisors Inc. ADV raised its stake in shares of Cognition Therapeutics by 33.4% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after acquiring an additional 24,050 shares during the period. Finally, CM Management LLC lifted its holdings in shares of Cognition Therapeutics by 14.3% in the 2nd quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $332,000 after acquiring an additional 25,000 shares during the last quarter. 43.35% of the stock is owned by institutional investors and hedge funds.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.